Investment details
- Closing date
- 17/03/26
- Fundraise target
- £150,000
- Fundraise maximum
- £220,000
- Minimum investment
- £5,000
- Equity stake
- 9.57%
- Exit Money Multiple
- Log in to view
- Exit IRR
- Log in to view
P3MO Ltd (“the Company” or “P3MO”) is an enterprise SaaS platform that simplifies complex modernisation and transformation projects – from multi-million-pound drug approval programmes in pharma to large-scale IT upgrades in government.
Transformation programmes in the public and private sectors fail at alarming rates - over 88% miss their objectives, wasting significant time and money.
Founded by experienced transformation project managers and tech developers, P3MO solves the challenges of enterprise transformation with a software platform designed for both managers and specialist delivery teams.
Multi-national customers include AstraZeneca, where 70+ global projects saw a 72% cut in governance time, a 90% reduction in reporting effort and a $1.2m saving through identification of a critical regulatory milestone.
Strong traction with £1.3m cumulative revenue to date, £280,000 Annual Recurring Revenue (‘ARR’) and a £2.2m near-term pipeline.
Other customers include Great Places Housing Group and a US and Colombia based petrochemical engineering firm.
We empower investors to stay in control of their capital, choose the companies they back and share in their journey to success.
Unlike most VCs, we are not a fund — we combine institutional-grade diligence and attractive tax benefits with the opportunity to co-invest alongside some of the UK’s leading VC firms.
P3MO Ltd (“the Company” or “P3MO”) is an enterprise SaaS platform that simplifies complex modernisation and transformation projects – from multi-million-pound drug approval programmes in pharma to large-scale IT upgrades in government.
Transformation programmes in the public and private sectors fail at alarming rates - over 88% miss their objectives, wasting significant time and money.
Founded by experienced transformation project managers and tech developers, P3MO solves the challenges of enterprise transformation with a software platform designed for both managers and specialist delivery teams.
Multi-national customers include AstraZeneca, where 70+ global projects saw a 72% cut in governance time, a 90% reduction in reporting effort and a $1.2m saving through identification of a critical regulatory milestone.
Strong traction with £1.3m cumulative revenue to date, £280,000 Annual Recurring Revenue (‘ARR’) and a £2.2m near-term pipeline.
Other customers include Great Places Housing Group and a US and Colombia based petrochemical engineering firm.

The Enterprise Investment Scheme (EIS) lets UK investors back growth companies with tax relief. Benefits include up to 30% income tax relief, plus Capital Gains, loss and Inheritance Tax advantages.
We want our investors to be fully aware of the downsides of investing as well as the potential benefits. It's therefore important to realise that investing always carries risks, including the loss of capital, illiquidity (the inability to sell assets quickly or without substantial loss in value), lack of dividends and share dilution. Alternative investments should still be made as part of a diversified portfolio.